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31

Objective: The newest findings on literature utilization relevant to gynecologic

32

oncology were published by Thomson Reuters during June 2013 as determinants of

33

journal standing. Our objective was to assess the different metrics reported for relative

34

impact and cost for journals relevant to gynecologic oncology.

35

Methods: 55 journals were evaluated for Impact Factor (IF), 5 Year IF, Immediacy

36

Index, Cited Half Life, Eigenfactor score (EF), Article Influence (AI) scores and

37

subscription costs obtained from publisher information.

38

Results: CA-A Cancer Journal for Clinicians had the highest IF (101.78) & AI (24.502).

39

The top EF cancer-specific journals were the Journal of Clinical Oncology, Cancer

40

Research, Clinical Cancer Research and Oncogene. Rankings for Gynecologic

41

Oncology (409 articles, 18,243 citations) were IF= 3.929, 43/55, EF=0.038, 28/55, AI=

42

1.099, 44/55, all higher than the previous year. The IF improved from the 5 year IF in

43

31 journals, including Gynecologic Oncology, 29/31. Subscription costs for Gynecologic

44

Oncology compared favorably to other journals.

45

Conclusions: The high utilization of review information in CA-A Cancer Journal for

46

Clinicians and Nature Review Cancer illustrated by the IF coupled with a relatively low

47

number of articles and short cited half life indicates that they serve as a leading source

48

of quoted cancer statistics (CA-A Cancer Journal for Clinicians). Rankings for

49

Gynecologic Oncology and the International Journal of Gynecologic Cancer have

50

improved Regardless of specialty size, the Impact Factor for Gynecologic Oncology is

51

respectably strong. The decreased IF in 44% of the journals may reflect the

52

international economy’s effect on cancer research.

53
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54

Introduction

55

The great commission of gynecologic oncology is to advance the field. To this end, new

56

information enters the literature and reaches individuals in practice and in training. We

57

have examined the extent to which this information is cited using information formulated

58

by Journal Citation Reports on the ISI Web of Knowledge [1]. In particular, this

59

examination compares gynecologic oncology-specific citations to citations in a variety of

60

journals that have published reports relevant to gynecologic oncology. The metrics

61

considered here move considerations of quality and worthiness to readers beyond

62

subjective views of reputation and command the attention of authors, sponsors and

63

advertisers, while suggesting how metric improvement can be achieved.

64
65

Methods

66

The 55 journals selected for inclusion in this report all had published findings relevant to

67

gynecologic oncology annually in the period in 2010-2012. Data on citations were

68

obtained from Journal Citation Reports (JCR) on the ISI Web of Knowledge published

69

by Thomson Reuters on subscription to the University of Kentucky libraries. The

70

following definitions are used:

71

Impact Factor 2012 = A/B where

72

A = the number of times that articles published in that journal in 2010 and 2011 were

73

cited by articles in indexed journals during 2012 and

74

B = the total number of "citable items" published by that journal in 2010 and 2011.

75

("Citable items" are usually articles, reviews, proceedings, or notes; not editorials or

76

letters to the editor) [2].
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77

5 Year Impact Factor: Average number of times articles from the journal published in

78

the last five years have been cited in 2012. This measure can better gauge the impact

79

of journals in fields where the influence of published research evolves over a longer

80

period of time [3].

81

Immediacy Index 2012 = A/B where

82

A = the number of times articles published by the journal in 2012 were cited in indexed

83

journals during 2012

84

B = the number of articles, reviews, proceedings or notes published by the journal in

85

2012 [4].

86

Cited Half Life: the median age of the articles in the journal that were cited by other

87

journals during 2012 [4].

88

Eigenfactor score: The Eigenfactor Score is measured using the 2012 citations in

89

relation to citable items from the five previous years. While the Impact Factor weighs

90

each citation to a journal equally, the Eigenfactor Score assigns a greater weight to

91

those citations coming from influential journals, allowing these journals to exert greater

92

influence in the determination of the rank of any journal which they reference. The

93

Eigenfactor Score does not count journal self-citations. The sum of Eigenfactor Scores

94

for all journals is 100; each journal's Eigenfactor Score is a percentage of this total

95

[5,6,7].

96

Article Influence Score: The journal's Eigenfactor Score divided by the fraction of

97

articles published by the journal. This determination is normalized so that the sum total

98

of articles from all journals is 1 [8].
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99

Thus, the mean Article Influence Score is 1.00 across the universe of journals.

100

Consequently, a score greater than 1.00 indicates that articles in that particular journal

101

have above-average influence, while a score less than 1.00 indicates that articles in that

102

journal have a below-average influence.

103

Cost Comparisons: Subscription costs were obtained by visiting the web sites for each

104

publication. Cost of some institutional subscriptions were obtained from the University

105

of Kentucky library.

106

Results

107

Metrics of Citation 55 journals were evaluated. The Proceedings of the National

108

Academy of Science of the United States published the most articles (3800) in 2012,

109

followed by the International Journal of Radiation Oncology Biology Physics (908), the

110

International Journal of Cancer (713), Cancer (650), and Clinical Cancer Research

111

(642), Table 1. Gynecologic Oncology published more articles in 2012 than 41 of the

112

journals (380 articles), while the International Journal of Gynecologic Cancer published

113

more articles than only 29 of the journals (236 articles). The articles cited in 2012 for

114

publications in 2010-11 define the Impact Factor and CA-A Cancer Journal for

115

Clinicians, the New England Journal of Medicine, the Lancet, Nature Review of Cancer

116

and the Journal of the American Medical Association ranked with the highest Impact

117

factors. Gynecologic Oncology ranked 43rd with an Impact Factor of 3.929, while the

118

International Journal of Gynecologic Cancer ranked 52nd with an Impact Factor of 1.941,

119

Table 1. Immediacy defined in terms of same year publication and citation was highest

120

for CA-A Cancer Journal for Clinicians, the New England Journal of Medicine, the

121

Lancet, the Journal of the American Medical Association and Lancet Oncology with
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122

Gynecologic Oncology ranking 42nd and the International Journal of Gynecologic

123

Cancer ranking 54th. The staying power of articles as defined by the median age

124

published in other journals in 2012 (Cited Half Life, in years) was highest for the

125

American Journal of Obstetrics & Gynecology, Cancer, the Journal of the National

126

Cancer Institute, Advances in Cancer Research and the Journal of the American

127

Medical Association with Gynecologic Oncology ranked 18th and the International

128

Journal of Gynecologic Cancer ranked 33rd, Table 1. Journal citations over a five year

129

period weighted for influential journals (2008-2012: Eigenfactor score) were highest for

130

the Proceedings of the National Academy of Science of the United States, the New

131

England Journal of Medicine, the Journal of Clinical Oncology, Lancet, and Cancer

132

Research, while Gynecologic Oncology ranked 28th and the International Journal of

133

Gynecologic Cancer ranked 40th. The Article Influence Score can be taken as a

134

measure of average influence of a journal’s articles five years after publication and by

135

this measure CA-A Cancer Journal for Clinicians, the New England Journal of Medicine,

136

Nature Review Cancer, Lancet, Cancer Cell and the Journal of the American Medical

137

Association scored highest (>10), while Gynecologic Oncology demonstrated above

138

average influence and the International Journal of Gynecologic Cancer showed

139

influence well below average.

140

Our survey of the 2011-2012 period revealed that ~15% of papers cited in Gynecologic

141

Oncology had been published in Gynecologic Oncology. In addition, surveying the

142

Gynecologic Oncology sections of the Journal of Clinical Oncology and of Cancer,

143

showed that ~17% and ~5% of the references were to papers published in Gynecologic

144

Oncology.
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145

Examination of Cost The most relevant subscription costs to gynecologic oncologists

146

are likely to be Gynecologic Oncology & the International Journal of Gynecologic

147

Cancer (Table 2 line A), Cancer and the Journal of Oncology (Table 2 line B) and

148

Obstetrics & Gynecology and the American Journal of Obstetrics and Gynecology

149

(Table 2 line C) totaling $2465 for members, $3003 for non-members and $8983 for

150

libraries (Table 2 line 3). The total subscription cost to libraries and institutions for all 55

151

journals considered here is $109,512 and is ~5 times the cost to individual members

152

(Table 2 line E). The mean cost to members of the 55 journals considered (Table 2 line

153

F: $554+129 (SEM)) compares well with the subscription cost of Gynecologic Oncology

154

($563 journal alone, $625 annual membership with complementary journal

155

subscription). However, subscription costs to the 6 journals most relevant to

156

gynecologic oncology (Table 2 line D) are much less than the mean cost of subscription

157

to 6 journals in the group of 55 journals under consideration (Table 2 line G).

158

Discussion

159

Ranking of the top 10 Impact Factor journals correlated well with the 5 year Impact

160

Factor, Immediacy Index and Article Influence Score in that the same journals ranked in

161

the top 10 for each of these categories (Table 3). Only one of the top 10 Impact Factor

162

journals was in the top 10 of the Number of Articles published in 2012, while 4 were in

163

the top 10 of Total Citations in 2012 and 4 were in the top ten rank for Cited Half-life.

164

Half of the top ten Impact Factor journals were among the journals with a top ten Eigen

165

Factor score (Table 3). Thus, annual citation performance is least correlated with the

166

number of articles published and connected about half the time with citations received,
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167

their median half life and Eigen Factor score. Consequently the metrics of citation are

168

not driven by the volume of articles published.

169

Gynecologic Oncology was above the median ranking in terms of articles published,

170

cited half-life and total citations for 2012 (Table 3), but it was below the median ranking

171

in all other measures. The International Journal of Gynecologic Cancer was above the

172

median ranking in articles published, but below the median ranking in all other

173

measures (Table 3).

174

Journals that publish reviews (CA-A Cancer Journal for Clinicians, Nature Review of

175

Cancer, Nature Reviews Clinical Oncology) are often cited with high immediacy and

176

short half-life because they are subject to annual updating (and do not necessarily occur

177

as citations in the most influential journals as indicated by the Eigen Factor metric).

178

Improvement in the current Impact Factor relative to the previous five years was

179

observed with 31 journals (56%), while the citation rate fell in 44% of the journals

180

considered. Thus, a narrow 6% margin separates the journals that demonstrate

181

improving citation from those that do not. Two tactics that could serve Gynecologic

182

Oncology to stay on track with improving annual Impact Factor scores could be to

183

include more reviews on gynecologic malignancies and to implement the inclusion of

184

annual statistics on gynecologic malignancies. Such statistics should include and

185

expand the gynecologic malignancies reported on beyond those covered in CA-A

186

Cancer Journal for Clinicians so that statistics uniquely available in Gynecologic

187

Oncology would push its Impact Factor higher. Importantly, gynecologic cancer reviews

188

and gynecologic cancer statistics should be made available on an Open Access basis to
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189

maximize their utilization and contribution to the Impact Factor of Gynecologic

190

Oncology.

191

Considered in the spectrum of medical specialty journals, Gynecologic Oncology is well-

192

positioned. Of twenty seven selected medical specialties that were examined (Table 4),

193

gynecologic oncology which ranked 22nd in physician number (n=1007 [9,10]) had it’s

194

lead journal’s Impact Factor ranked 13th. The Impact Factor for Gynecologic Oncology

195

(3.929) was better than the median Impact Factor for journals in small specialties (49-

196

1854 physicians, median = 2.649) and better than the median Impact Factor for the lead

197

journals of all specialties considered here (median = 3.569). Mid sized specialties

198

(4493-19131 physicians) had lead journals with a greater median Impact Factor (5.644).

199

Large specialties (27651-90269 physicians) had a median Impact Factor (3.877) slightly

200

lower than Gynecologic Oncology. Considered in these terms, the current Impact

201

Factor for Gynecologic Oncology is quite strong and respectable among journals for

202

medical specialties. Impact Factors >10 considered here (Table 1) were either for multi-

203

specialty journals or multi-discipline journals. We believe that Gynecologic Oncology

204

currently serves both private practice and academic gynecologic oncologists extremely

205

well because of it’s targeted content. We also believe that as a group, gynecologic

206

oncologists are proud and very competitive. In this regard, we feel that an expectation

207

exists for journal metrics that continuously improve. We believe that there is no down-

208

side to improving these metrics for those in private practice as well as in academic

209

medicine and that the better the journal metrics, the better the Society of Gynecologic

210

Oncologists will fair in the eyes of advertisers and sponsors.
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211

In summary, Gynecologic Oncology performs well in terms of citation metrics and cost.

212

It should be possible to further improve these metrics by introducing reviews and

213

statistics on gynecologic malignancies.

214

The role of the medical journal must loom in the perspective of practitioners as a

215

trustworthy source of information that carries both influence and advice. In this role it

216

unifies the past with the present and must be counted on to have an ongoing outreach

217

to future discovery and innovation. Authors want to publish in a quality place that draws

218

attention to their work, a place that will be good enough to contribute to their career

219

advancement. Readers want a source of significant information that is worthy of their

220

time and subscription cost. The measure of quality and time worthiness has moved

221

beyond subjective evaluation and now takes on the metrics of utilization, which while

222

not totally perfect, provide comparative numeric standards that, like it or not, do

223

command attention, especially of sponsors and advertisers. Not to be overlooked are

224

new models embracing digital communication that have an influence on authors,

225

readers, patients, sponsors and advertisers through information that reaches them

226

through the Internet, Open Access, social media, blogs, Twitter, search engines, etc. In

227

the end, the metrics of citation utilization will both influence and be influenced by an

228

evolution of awareness brought forward by technology. As this occurs, journals must

229

not lose sight of the significance of peer review [2]. This is the single most important

230

process that can re-craft the submission by utilizing expert reviewers that raise

231

questions, the answers to which can be incorporated in the final publication to enhance

232

it’s quality [11]. In the end, with the literature practically “bursting at the seams” with the

233

diverse opportunities made possible by the digital revolution [12], it will be quality that
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234

determines readership and citations. The future holds but one thing and that is to

235

continue to evolve so that specialty information is useful to those in the field of

236

gynecologic oncology [13].

237
238
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